{"id":1318,"date":"2020-06-12T11:59:50","date_gmt":"2020-06-12T15:59:50","guid":{"rendered":"http:\/\/altitudeclinic.com\/blog\/?p=1318"},"modified":"2022-05-30T19:03:30","modified_gmt":"2022-05-30T23:03:30","slug":"covid-19-pubs","status":"publish","type":"post","link":"https:\/\/altitudeclinic.com\/blog\/2020\/06\/covid-19-pubs\/","title":{"rendered":"COVID-19 Publications, interviews & conferences"},"content":{"rendered":"\n
\"\"
High Altitude Pulmonary and Pathology Institute in La Paz, Bolivia 3500m<\/figcaption><\/figure>\n\n\n\n

As far as we know, we were the first in the world to propose that the U-V at high altitude would be a protective disinfectant in the COVID Pandemic. Originally, in Dec 2017 on a paper on Longevity at high altitude(Se ref. 1, below). Then I wrote a newspaper article about it when the Pandemic started to arrive in Bolivia on April 5th, 2020(3). My daughter Natalia Zubieta-DeUrioste, M.D., and I teamed up with another Bolivian Jorge Soliz Ph.D. and Christian Arias from Laval University who postulated that the lower amount of ACE2 receptors in the lungs at high altitude could also be a protective factor at high altitude. We participated in the U-V section. The other coauthors of that paper were several Bolivian Ph.D. students and an Australian Ph.D. (4). Likewise, we wrote of multiple diseases in COVID-19 early on May 5, 2020 (5) currently under peer review. Furthermore, I created the term “Pneumolysis” to describe what happens in COVID-19 and presented it for the first time in the INTERNATIONAL CONFERENCE ON CORONA VIRAL GENOME, in India (See the banner below). We feel proud to be able to contribute with our knowledge accumulated over 50 years of work at IPPA Just celebrated on July 9th, 2020, to this COVID Pandemic. <\/p>\n\n\n\n

Below, is the evolution of this story.<\/p>\n\n\n\n

Prof. Dr. Gustavo Zubieta-Calleja, M.D.<\/p>\n\n\n\n

Our papers on COVID<\/h2>\n\n\n\n